Quick summary
Lixisenatide is a once-daily short-acting GLP-1 receptor agonist derived from exendin-4, FDA-approved in 2016 as Adlyxin. It was particularly effective at blunting postprandial glucose spikes but was discontinued in the US in January 2023 due to competition from newer agents.
Overview
Lixisenatide is a once-daily short-acting GLP-1 receptor agonist derived from exendin-4, modified at the C-terminus with deletion of one proline and addition of six lysine residues. FDA-approved in 2016 as Adlyxin (Sanofi), it distinguished itself from other GLP-1 agents through its pronounced postprandial glucose-lowering effect via potent gastric emptying inhibition. Lixisenatide was discontinued in the US market in January 2023.
Mechanism of action
Lixisenatide binds selectively and with high affinity to the GLP-1 receptor, a class B GPCR. Its C-terminal hexalysine extension confers DPP-4 resistance and receptor binding characteristics that differ from native GLP-1. Unlike long-acting GLP-1 agents, lixisenatide's short half-life (~3 hours) produces a pronounced and transient inhibition of gastric emptying concentrated around the postprandial period, making it particularly effective at blunting after-meal glucose spikes. Mechanistically, it stimulates glucose-dependent insulin secretion from beta cells via cAMP/PKA and PI3K/Akt pathways, suppresses glucagon from alpha cells, and activates hypothalamic GLP-1R to promote satiety. The acute gastric emptying effect is more pronounced than with longer-acting agents, explaining its differential glucose-lowering profile (more postprandial vs. fasting glucose effect).
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| type 2 diabetes glycemic control | subcutaneous | 10–20 mcg | once daily | Start at 10 mcg once daily for 14 days, then increase to maintenance dose of 20 mcg once daily. Inject within 1 hour before the first meal of the day. |
| postprandial glucose control (add-on to basal insulin) | subcutaneous | 10–20 mcg | once daily | Same titration as monotherapy. Particularly studied as add-on to insulin glargine in GetGoal-Duo trials. Monitor for hypoglycemia and reduce insulin dose as needed. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The GetGoal clinical program (12 pivotal trials) demonstrated HbA1c reductions of 0.7–1.0% and modest weight loss of 1–2 kg vs. placebo over 24 weeks. The ELIXA cardiovascular outcomes trial (6,068 patients, median 2.1 years) demonstrated cardiovascular safety (noninferiority) but not superiority for MACE vs. placebo — the first cardiovascular outcomes trial for any GLP-1 agonist, completed in 2015. Lixisenatide showed particular efficacy in controlling 2-hour postprandial glucose in combination with basal insulin.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Lixisenatide for synergistic effects.
Legal status
FDA-approved July 2016. Voluntarily withdrawn from the US market by Sanofi effective January 1, 2023, due to commercial reasons (competition from newer GLP-1 agents). Still available in some international markets as Lyxumia. Was a Schedule-unscheduled prescription drug. No longer obtainable in the US through standard pharmacy channels.
Sourcing & access
Prescription required
Lixisenatide is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Lixisenatide (brand: Adlyxin/Lyxumia) is a once-daily GLP-1 receptor agonist derived from exendin-4 with a C-terminal hexalysine extension. FDA-approved in 2016, it was voluntarily withdrawn from the US market by Sanofi in January 2023 due to commercial competition.
Lixisenatide's short half-life (~3 hours) produces pronounced transient inhibition of gastric emptying around meals, making it particularly effective at blunting postprandial glucose spikes. It also stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner.
The ELIXA cardiovascular outcomes trial in 6,068 patients over a median 2.1 years demonstrated cardiovascular safety with noninferiority to placebo for major adverse cardiovascular events. Common side effects include nausea at 25 percent incidence, vomiting at 10 percent, diarrhea, headache, injection site reactions, and hypoglycemia when combined with insulin or sulfonylureas. Rare anaphylaxis and pancreatitis have been reported.
Lixisenatide was voluntarily withdrawn from the US market by Sanofi effective January 2023 due to competition from newer GLP-1 agents like semaglutide. It may still be available in some international markets as Lyxumia.
Research references
- Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)PubMed
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA)PubMed
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA)PubMed
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA trialPubMed